Circio Holding ASA
Entity

  • Circio Holding ASA

    Created in 2010
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    4,156

  • Activities

    deeptech biotech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Lilleakerveien 2C, 0283 Oslo, Norway

    Oslo

    Norway

  • Employees

    Scale: 11-50

    Estimated: 21

  • Engaged corporates

    0
    0 0

  • Added in Motherbase

    1 year, 5 months ago
Description
  • Value proposition

    Developing novel circular RNA and immunotherapy medicines.

    Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications.

    The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.

  • Circio

    Circio Holding ASA (OSE:TRVX, to be changed to CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines.

    • https://www.circio.com/en/
Corporate interactions BETA
Corporate TypeTweets Articles
No interactions
Similar entities
Last news
Show all articles
Social network dynamics